Go Pro
NASDAQ:SWKH

SWK Q3 2025 Earnings Report

SWK EPS Results

Actual EPS
$0.59
Consensus EPS
$0.34
Beat/Miss
Beat by +$0.25
One Year Ago EPS
N/A

SWK Revenue Results

Actual Revenue
$13.72 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

SWK Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
Thursday, November 6, 2025
Conference Call Time
4:00PM ET

SWK Earnings Headlines

Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.tc pixel
SWKHL: Attractive Baby Bond After The Merger, 9% Coupon
See More SWK Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like SWK? Sign up for Earnings360's daily newsletter to receive timely earnings updates on SWK and other key companies, straight to your email.

About SWK

SWK (NASDAQ:SWKH) Holdings Corporation, offers specialty finance and asset management services in the United States. It operates in two segments, Finance Receivables and Pharmaceutical Development. The Finance Receivables segment provides customized financing solutions to a range of life science companies, including companies in the biotechnology, medical device, medical diagnostics and related tools, animal health, and pharmaceutical industries, as well as institutions and inventors. This segment also offers non-discretionary investment advisory services to institutional clients in separately managed accounts to invest in life science finance. The Pharmaceutical Development segment provides customers pharmaceutical development, formulation, and manufacturing services, as well as formulation solutions built around its proprietary oral drug delivery technologies, the Peptelligence platform. It also offers intellectual property licensing business. The company was formerly known as Kana Software, Inc. and changed its name to SWK Holdings Corporation in December 2009. SWK Holdings Corporation was incorporated in 1996 and is headquartered in Dallas, Texas.

View SWK Profile